Abstract
Tazobactam/piperacillin (TAZ/PIPC; YP-14) was administered to eight inpatients with respiratory tract infections.
Among the eight cases, three had bacterial pneumonia, two had mycoplasmal pneumonia, one had lung abscess, one had interstitial pneumonia with infection and one had pyothorax. TAZ/PIPC was administered at 2.5g twice a day for three to fifteen days. Excellent efficacy, good efficacy and poor efficacy were observed in two cases, two cases and one case, respectively, excluding the two cases of mycoplasmal pneumonia and the one case of interstitial pneumonia with infection
Concerning bacteriological effects, two strains of Streptococcus pneumoniae were eradicated, but one strain of Streptococcus milleri was unknown among the three strains of pathogenic bacteria isolated in three cases.
Neither adverse reactions nor abnormalities in the results of clinical laboratory examinations were observed in any patients.
On the basis of the above results, TAZ/PIPC is concluded to be an extremely useful agent in respiratory tract infections.
